PURPOSE: Early detection and improvements in treatment have increased survival after colorectal cancer (CRC), but studies investigating the multidimensional nature of treatment-related symptoms are rare. The aim of this study was therefore to describe the prevalence, frequency, and severity of symptoms and the distress they cause during the early treatment of patients with CRC undergoing chemotherapy. METHODS: Consecutive outpatients were asked to rate their symptoms during cycle 2 or 3 of chemotherapy, using the Memorial Symptom Assessment Scale. RESULTS: A total of 104 patients, 58 men and 46 women, evaluated their symptoms of the preceding week at one point during the treatment. The mean number of symptoms was 10.3 (SD, 7.7; range, 0-32). Highly prevalent symptoms were numbness/tingling in the hands/feet (64 %), lack of energy (62 %), feeling drowsy (49 %), and nausea (45 %). Symptoms with the highest scores for frequency, severity, and distress were lack of energy followed by difficulty in sleeping and numbness in the hands/feet. Lack of energy was noted as occurring almost constantly by 26 % and was rated as being severe or very severe by 12 % and as quite distressing or very distressing by 15 %. CONCLUSIONS: This study shows that patients with CRC receiving chemotherapy experience several distressing symptoms early in the treatment phase. In order to provide symptom control, oncology staff should consider evaluating the patient's symptoms early during treatment and plan adequate measures to minimize the impact of treatment-induced toxicity.
PURPOSE: Early detection and improvements in treatment have increased survival after colorectal cancer (CRC), but studies investigating the multidimensional nature of treatment-related symptoms are rare. The aim of this study was therefore to describe the prevalence, frequency, and severity of symptoms and the distress they cause during the early treatment of patients with CRC undergoing chemotherapy. METHODS: Consecutive outpatients were asked to rate their symptoms during cycle 2 or 3 of chemotherapy, using the Memorial Symptom Assessment Scale. RESULTS: A total of 104 patients, 58 men and 46 women, evaluated their symptoms of the preceding week at one point during the treatment. The mean number of symptoms was 10.3 (SD, 7.7; range, 0-32). Highly prevalent symptoms were numbness/tingling in the hands/feet (64 %), lack of energy (62 %), feeling drowsy (49 %), and nausea (45 %). Symptoms with the highest scores for frequency, severity, and distress were lack of energy followed by difficulty in sleeping and numbness in the hands/feet. Lack of energy was noted as occurring almost constantly by 26 % and was rated as being severe or very severe by 12 % and as quite distressing or very distressing by 15 %. CONCLUSIONS: This study shows that patients with CRC receiving chemotherapy experience several distressing symptoms early in the treatment phase. In order to provide symptom control, oncology staff should consider evaluating the patient's symptoms early during treatment and plan adequate measures to minimize the impact of treatment-induced toxicity.
Authors: Ann M Berger; Jean L Grem; Constance Visovsky; Heather A Marunda; Justin M Yurkovich Journal: Oncol Nurs Forum Date: 2010-11 Impact factor: 2.172
Authors: Craig D Blinderman; Peter Homel; J Andrew Billings; Sharon Tennstedt; Russell K Portenoy Journal: J Pain Symptom Manage Date: 2009-02-20 Impact factor: 3.612
Authors: R K Portenoy; H T Thaler; A B Kornblith; J M Lepore; H Friedlander-Klar; E Kiyasu; K Sobel; N Coyle; N Kemeny; L Norton Journal: Eur J Cancer Date: 1994 Impact factor: 9.162
Authors: Ilufredo Y Tantoy; Anand Dhruva; Janine Cataldo; Alan Venook; Bruce A Cooper; Steven M Paul; Jon D Levine; Yvette P Conley; Frances Cartwright; Kathryn Lee; Fay Wright; Christine Miaskowski Journal: J Gastrointest Oncol Date: 2017-02
Authors: Michael Jefford; Karla Gough; Allison Drosdowsky; Lahiru Russell; Sanchia Aranda; Phyllis Butow; Jo Phipps-Nelson; Jane Young; Mei Krishnasamy; Anna Ugalde; Dorothy King; Andrew Strickland; Michael Franco; Robert Blum; Catherine Johnson; Vinod Ganju; Jeremy Shapiro; Geoffrey Chong; Julie Charlton; Andrew Haydon; Penelope Schofield Journal: Oncologist Date: 2016-06-15
Authors: Claire J Han; Kerryn Reding; Bruce A Cooper; Steven M Paul; Yvette P Conley; Marilyn Hammer; Fay Wright; Frances Cartwright; Jon D Levine; Christine Miaskowski Journal: J Pain Symptom Manage Date: 2019-05-09 Impact factor: 3.612
Authors: Catherine E Mosher; Ekin Secinti; Shelley A Johns; Bert H O'Neil; Paul R Helft; Safi Shahda; Shadia I Jalal; Victoria L Champion Journal: Qual Life Res Date: 2017-06-10 Impact factor: 4.147
Authors: Catherine E Mosher; Ekin Secinti; Wei Wu; Deborah A Kashy; Kurt Kroenke; Jonathan B Bricker; Paul R Helft; Anita A Turk; Patrick J Loehrer; Amikar Sehdev; Ahmad A Al-Hader; Victoria L Champion; Shelley A Johns Journal: Palliat Med Date: 2022-05-30 Impact factor: 5.713
Authors: Ying Sheng; Janet S Carpenter; Charles D Elomba; Jennifer S Alwine; Min Yue; Caitlin A Pike; Chen X Chen; James E Tisdale Journal: Womens Midlife Health Date: 2021-05-31
Authors: Yufen Lin; Donald E Bailey; Sharron L Docherty; Laura S Porter; Bruce A Cooper; Steven M Paul; Kord M Kober; Marilyn J Hammer; Fay Wright; Laura B Dunn; Yvette P Conley; Jon D Levine; Christine Miaskowski Journal: Support Care Cancer Date: 2021-01-16 Impact factor: 3.359
Authors: Catherine E Mosher; Rebecca N Adams; Paul R Helft; Bert H O'Neil; Safi Shahda; Nicholas A Rattray; Victoria L Champion Journal: Support Care Cancer Date: 2015-11-04 Impact factor: 3.359